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Objective: To analyze the characteristic of coagulation function in non-small cell lung
cancer patients with acute cerebral infarction as the initial symptom.
Methods: Cases diagnosed as non-small cell lung cancer in our hospital from January
2015 to January 2016 were used for study. Fifteen cases with acute cerebral infarction as
the initial symptom were included in experimental group. Thirty-three cases with no
initial symptom on acute cerebral infarction were included in control group. Clinical data
in patients of two groups were collected, including general information, coagulation
function index, thrombelastogram index.
Results: The prothrombin time (PT) [(9.69 ± 1.42) vs. (13.04 ± 1.96) s], activated partial
thromboplastin time (APTT) [(30.14 ± 5.79) vs. (39.34 ± 7.63) s], international
normalized ratio (INR) [(0.76 ± 0.10) vs. (1.35 ± 0.22)], coagulation reaction time (R)
[(4.76 ± 0.79) vs. (6.11 ± 0.93) min], and blood clot formation time (K) [(1.73 ± 0.21) vs.
(6.11 ± 0.93) min] in patients of experimental group were obviously lower than that of in
control group. Fibrinogen (FIB) [(5.43 ± 0.89) vs. (2.14 ± 0.36) g/L], D-dimer
[(0.84 ± 0.17) vs. 0.30 ± 0.06) mg/L], the maximum amplitude of thrombus (MA)
[(65.62 ± 10.34) vs. (48.69 ± 8.61) mm], and a-angle [(68.12 ± 9.51) vs. (60.37 ± 10.29)
deg] in patients of experimental group were obviously higher than that in control group.
PT, APTT, INR, R value, and K value in patients of tumor node metastasis (TNM) Stage
III–IV were signiﬁcantly lower than that in TNM Stage I–II, and FIB, D-dimer, MA, a-
angle were all higher than that in patients of TNM Stage I–II. PT, APTT, INR, R value, K
value in patients with lymphatic metastasis were signiﬁcantly lower than that in patients
with no lymph node metastasis, and FIB, D-dimer, MA, a-angle were obviously higher
than that in patients with no lymph node metastasis.
Conclusions: Patients with non-small cell lung cancer have hypercoagulability and
hyperﬁbrinolysis with acute cerebral infarction as the initial symptom, and coagulation
function involved in the development of lung disease.1. Introduction
Lung cancer is one of the most malignant tumors worldwide.
The occurrence rate and case fatality rate of lung cancer in our
country are rising in recent year[1,2]. Non-small cell lung cancer is
the most common type of lung cancer, which accounts for over
90% of all lung cancers. Patients are lack of clinical symptom in
the early stage, and most patients have been developed to
advanced stage at the time of diagnosis, and its prognosisconditions is relatively worse. Although the new targeted drug
and chemotherapy drug are constantly developing, the survival
rate is still very low[3–6]. Some studies have proved that blood in
abnormal hypercoagulability state and the abnormal of
coagulation function will increase the risk of arterial embolism
in the disease progresses of non-small cell lung cancer[7,8]. Acute
cerebral infarction is the initial symptom for some patients with
lung cancer, and the existence of lung malignancies was found
in the process of diagnosis and treatment of cerebral
infarction[9,10]. At present, fewer researches have been done on
lung cancer patients with acute cerebral infarction as the initial
symptom, and also lack of understanding on this kind of
clinical features. Correctly understand the changes of
coagulation function in the pathogenic process of lung cancer
not only help to early predict the occurrence risk of cerebral
infarction and prevent the occurrence of cerebral infarction, butBY-NC-ND license (http://
Table 1
General data in patients of two groups.





Gender (male/female) 10/5 23/10 > 0.05
Age (year) 58.0 ± 7.0 55.0 ± 8.0 > 0.05
BMI (kg/m2) 22.1 ± 4.5 21.3 ± 4.9 > 0.05
TNM staging
(I/II/III/IV)
3/5/5/2 6/10/12/5 > 0.05
Lymphatic metastasis 4 9 > 0.05
Table 2






PT (s) 9.69 ± 1.42 13.04 ± 1.96 < 0.05
APTT (s) 30.14 ± 5.79 39.34 ± 7.63 < 0.05
INR 0.76 ± 0.10 1.35 ± 0.22 < 0.05
FIB (g/L) 5.43 ± 0.89 2.14 ± 0.36 < 0.05
D-dimer (mg/L) 0.84 ± 0.17 0.30 ± 0.06 < 0.05
MA (mm) 65.62 ± 10.34 48.69 ± 8.61 < 0.05
R (min) 4.76 ± 0.79 6.11 ± 0.93 < 0.05
K (min) 1.73 ± 0.21 2.48 ± 0.34 < 0.05
a-Angle (deg) 68.12 ± 9.51 60.37 ± 10.29 < 0.05
Table 3
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cancer. In this study, we analyzed the clinical features of acute
cerebral infarction accompanied with lung cancer.
2. Materials and methods
2.1. Case data
Cases diagnosed as non-small cell lung cancer in our hospital
from January 2015 to January 2016 were selected in this study.
Inclusion criteria: age >18 years; patients were diagnosed as non-
small cell lung cancer by biopsy pathology; patients were the ﬁrst
time diagnosis and received no anti-cancer treatment before, and
have complete clinical data. Exclusion criteria: patients were
diagnosed as other types of lung cancer; patients once received the
anti-cancer therapies of radiotherapy, chemotherapy, and targeted
therapy, etc.; patients involved the presence of distant metastases,
and had the medical history of ischemic stroke. Patients with acute
cerebral infarction as the initial symptom conformed to the diag-
nostic criteria of acute cerebral infarction in the Fourth National
Conference on Cerebrovascular Disease (1995)[11]. New infarction
lesions can be explained by using head CT scan to exclude
hemorrhage, as well as using skull magnetic resonance imaging
scanning and diffusion weighted imaging to conﬁrm the
occurrence of long T1, long T2 and high diffusion weighted
imaging signals in head.
2.2. Collection methods of clinical information
Case data were conducted with retrospective analysis for
patients. General data including gender, age, body mass index
(BMI) index, tumor node metastasis (TNM) staging, lymphatic
metastasis. Analytical methods of coagulative function index:
after taking peripheral blood, coagulation analyzer was used to
detect prothrombin time (PT), activated partial thromboplastin
time (APTT), international normalized ratio (INR), ﬁbrinogen
(FIB), and D-dimer. Thrombelastogram analytical methods:
TEG-500 thromboelastography (Haemoscope Company, Hong
Kong) was used to detect the maximum amplitude of thrombus
(MA), coagulation reaction time (R), blood clot formation time
(K), and blood clot formation rate (a-angle).
2.3. Statistical analysis
Data were inputted and analyzed by SPSS version 19.0.
Measurement data was expressed by mean ± SD, and t-test was
used for the analysis between two groups. Enumeration data
were expressed by frequency and analyzed by Chi-square test.
P < 0.05 was considered as statistical signiﬁcance.Coagulation function in patients of experimental group in different TNM
staging.





PT (s) 12.13 ± 1.98 7.24 ± 1.03 < 0.05
APTT (s) 35.25 ± 6.94 29.14 ± 5.88 < 0.05
INR 0.98 ± 0.13 0.61 ± 0.09 < 0.05
FIB (g/L) 3.98 ± 0.67 6.23 ± 0.72 < 0.05
D-dimer (mg/L) 0.59 ± 0.11 1.09 ± 0.23 < 0.05
MA (mm) 55.34 ± 8.92 71.34 ± 12.35 < 0.05
R (min) 5.23 ± 0.84 3.24 ± 0.56 < 0.05
K (min) 2.04 ± 0.32 1.39 ± 0.18 < 0.05
a-Angle (deg) 63.36 ± 8.22 74.10 ± 11.28 < 0.053. Results
3.1. General data in patients of two groups
Among the patients with non-small cell lung cancer, 15 cases
of acute cerebral infarction as the initial symptom were included
in experimental group. Thirty-three cases with no acute cerebral
infarction as the initial symptom were included in control group.
In experimental group, 10 cases were males and 5 cases were
females, with mean age of (58.0 ± 7.0) years, BMI [(22.1 ± 4.5)
kg/m2], 3 cases in TNM Stage I, 5 cases in Stage 2, 5 cases inStage III, 2 cases in Stage IV, 4 cases in lymphatic metastasis. In
control group, 23 cases were males, and 10 cases were females,
with mean age of (55.0 ± 8.0) years, BMI [(21.3 ± 4.9) kg/m2], 6
cases in TNM Stage I, 10 cases in Stage II, 12 cases in Stage III,
5 cases in Stage IV, 9 cases in lymphatic metastasis. According
to statistic analysis, gender, age, BMI index, TNM staging, and
lymphatic metastasis in patients of experimental group have no
difference with patients in control group (Table 1).3.2. Coagulation function in patients of two groups
PT, APTT, INR, R, and K in patients of experimental group
were obviously lower than that of in control group. FIB, D-
dimer, MA, and a-angle in patients of experimental group were
signiﬁcantly higher than that of in control group (Table 2).3.3. Coagulation function in patients of experimental
group in different TNM staging
PT, APTT, INR, R, K in patients of TNM Stage III–IV were
obviously lower than that of in patients of TNM Stage I–II. FIB,
D-dimer, MA, a-angle in patients of experimental group were
signiﬁcantly higher than that of in patients of TNM Stage I–II
(Table 3).
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group in different lymphatic metastasis conditions
PT, APTT, INR, R, K in patients with lymphatic metastasis
were obviously lower than that of in patients with on lymphatic
metastasis. FIB, D-dimer, MA, a-angle in patients of experi-
mental group were signiﬁcantly higher than that of in patients
with lymphatic metastasis (Table 4).Table 4
Coagulation function in patients of experimental group in different
lymphatic metastasis conditions.
Parameters No lymph node metastasis
(n = 11)
Lymphatic
metastasis (n = 4)
P
PT (s) 13.94 ± 2.12 6.03 ± 0.91 < 0.05
APTT (s) 36.61 ± 6.52 27.83 ± 6.12 < 0.05
INR 1.06 ± 0.15 0.55 ± 0.07 < 0.05
FIB (g/L) 4.03 ± 0.79 6.03 ± 0.67 < 0.05
D-dimer (mg/L) 0.51 ± 0.10 1.20 ± 0.28 < 0.05
MA (mm) 51.61 ± 8.35 75.16 ± 11.18 < 0.05
R (min) 5.61 ± 0.78 3.03 ± 0.52 < 0.05
K (min) 2.11 ± 0.33 1.32 ± 0.16 < 0.05
a-Angle (deg) 62.12 ± 8.41 75.22 ± 10.85 < 0.054. Discussion
States of hypercoagulability and hyperﬁbrinolysis in patients
with malignant tumor has received more and more attentions in
recent years. Hypercoagulability and hyperﬁbrinolysis will in-
crease the occurrence risk of embolism in artery thrombosis,
causing the increasement of occurrence rate in myocardial
infarction, cerebral infarction and other disease[12–15]. Some
patients show acute cerebral infarction and myocardial
infarction as the initial symptoms before they were diagnosed
as malignant tumor, in which some of these patients have
already developed into middle and advanced stage of tumour
and the lymphatic metastasis has been made[16–18]. At present,
corresponding research and cognition are deﬁcient in the
clinical features of lung cancer patients with acute cerebral
infarction as the initial symptoms. Among patients with non-
small cell lung cancer in this study, 15 cases of acute cerebral
infarction were set as the initial symptoms, in which the pro-
portion of advanced malignant tumor was 7/15, 4/15 in
lymphatic metastasis, suggesting that most patients show acute
cerebral infarction as the initial symptom before diagnosing as
the non-small cell lung cancer, and patients in middle and
advanced stage and lymphatic metastasis occupied the certain
proportion in this part of patients.
PT and APTT mainly reﬂected the content and function of
various blood coagulation factors in endogenous and exoge-
nous coagulation system. Endogenous coagulation pathway
can be activated when blood contact with negative foreign
material on its surface. Exogenous coagulation pathway can be
activated when tissue factors trigger cascade reaction[19–21].
Prolonged APTT and PT are the main performance of body
hypercoagulability. Besides, hyperfunction of ﬁbrinolytic
system is another performance of body hypercoagulability.
Fibrinogen and D-dimer are the speciﬁc indexes of reﬂecting
ﬁbrinolytic system activity. Fibrinogen was originally
synthesized with liver, after being activated, it transforms
into ﬁbrinogen polymer cross-linking of various hemocyte to
form blood clot[22,23]. D-dimer is the product of cross-linkedﬁbrin after cleavage, which can reﬂect the formation and
degradation degree of ﬁbrin[24,25]. We analyzed the coagulation
function index in non-small cell lung cancer patients with acute
cerebral infarction as the initial symptom, discovering that
APTT and PT in patients of experimental group were obviously
lower than of in control group, and ﬁbrinogen and D-dimer
were signiﬁcantly higher than that of in control group, which
indicated that lung cancer with acute cerebral infarction as the
initial symptom has hypercoagulability and hyperﬁbrinolysis.
Thrombelastography is a newly developed adjuvant diag-
nostic method for testing aggregation, coagulation and ﬁbrino-
lysis of platelet, which can reﬂect the content and function of
blood coagulation factor, ﬁbrinogen and blood platelet to further
access the coagulation and ﬁbrinolytic statuses of body[26,27]. R
value and K value are the coagulation reaction time and
formation time of blood clot respectively to reﬂect the
formation velocity of sludged blood and steady the formation
time of sludged blood, which mainly related to the content of
ﬁbrinogen and activity of platelet[28]. a-Angle, also called as
coagulation angle, representing the formation rate of blood
clot, which is inﬂuenced by the content of ﬁbrinogen and
activity of platelet[29]. MA reﬂects the strength and stability of
sludged blood after the formation that mainly impacted by the
platelet aggregative function[30]. We analyzed the coagulation
function index in non-small cell lung cancer patients with
acute cerebral infarction as the initial symptom, discovering that
R value and K value in patients of experimental group were
shorter than of in control group, and MA and a-angle were
greater than that of in control group, which indicated that lung
cancer patient with acute cerebral infarction as the initial
symptom has higher content of ﬁbrinogen, activity of platelet
and stronger aggregation function, and the overall performance
showed hypercoagulability.
In the development process of disease of non-small cell lung
cancer, correctly understand the change condition of coagulation
function can not only beneﬁt for early predict the occurrence risk
of cerebral infarction and prevent the occurrence of cerebral
infarction, but also provide the basis for early diagnosis and
screening of lung cancer. In order to deﬁne the relationship be-
tween the change of coagulation function and the occurrence and
development of lung cancer, we analyzed the inﬂuence of
different TNM staging on coagulation function. Results showed
that PT, APTT, INR, R value, and K value in patients of TNM
Stage III–IV were signiﬁcantly lower than that of in patients of
TNM Stage I–II. This reﬂects the development of lung disease
accompanied by changes of coagulation. On this basis, further
analysis of the inﬂuence of lymph node metastasis status on
coagulation function can conclude that PT, APTT, INR, R value
and K value in patients with lymphatic metastasis were signiﬁ-
cantly lower than that of in patients with non lymph node
metastasis, and FIB, D-dimer, MA and a-angle were signiﬁcantly
higher than that of in patients with non lymph node metastasis. It
was concluded that the changes of coagulation function in pa-
tients with lung cancer related to the metastasis of lymphonodus.
In conclusion, non-small cell lung cancer patients with acute
cerebral infarction as the initial symptom have hypercoagula-
bility and hyperﬁbrinolysis, and its the coagulation function was
associated with the development of lung cancer.
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